Cinclus Pharma

CINPHA · Nasdaq Stockholm · Healthcare

12.94SEK −2.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: −26.0%

Performance

1 month

+4.2%

1 year

−26.0%

3 years, per year

–

5 years, per year

–

Largest fall, 3 years

−73.1%

Below the peak now

−63.0%

Volatility, 1 year

43.0%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

2.9

Dividend yield

0.0%

Return on equity

−132.9%

Net margin

–

Market value

60 m USD

Quality, value and trend

Where Cinclus Pharma stands against every Nordic stock today. 100 is best.

Quality31

Profitability and a sound balance sheet over time. Better than 31% of Nordic stocks.

Value6

The price measured against earnings, assets and cash flow. Better than 6% of Nordic stocks.

Trend35

The price development over the past year. Better than 35% of Nordic stocks.

Combined7

Quality, value and trend together. Better than 7% of Nordic stocks.

About Cinclus Pharma

Cinclus Pharma is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 17 employees.

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis